Quality of Life ‐ not reported · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Scar severity ‐ 585‐nm pulsed‐dye laser (PDL) plus triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU) versus TAC plus 5‐FU ‐ blinded observer assessment of good to excellent scar improvement ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes scar severity ‐ 585‐nm pulsed‐dye laser (PDL) plus triamcinolone… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.75 [0.95, 3.22]
Studies not reported
Very low
Scar severity ‐ 585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU ‐ patient self‐assessment of good to excellent scar improvement ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes scar severity ‐ 585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU ‐… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.36 [0.85, 2.18]
Studies not reported
Very low
Scar severity ‐ carbon dioxide (CO2) laser plus TAC versus cryosurgery plus TAC. Mean percentage reduction ‐ blinded observer assessment ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Scar severity ‐ CO2 laser plus TAC versus cryosurgery plus TAC Mean percentage reduction ‐ patient self‐assessment score (higher scores = worse scar appearance) ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Incidence of treatment‐related adverse effects: CO2 laser plus TAC versus cryosurgery plus TAC ‐ atrophy ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects: CO2 laser plus TAC… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.13 [0.7, 1.82]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC versus cryosurgery plus TAC ‐ erythema ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.5 [0.47, 4.78]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC versus cryosurgery plus TAC ‐ telangiectasia ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC… compared with other treatment (very low certainty).
1 finding from 1 review
RR 0.33 [0.07, 1.52]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC versus cryosurgery plus TAC ‐ hypopigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC… compared with other treatment (very low certainty).
1 finding from 1 review
RR 0.6 [0.16, 2.29]
Studies not reported
Very low
Scar severity ‐ Neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ blinded observer assessment of good to excellent scar improvement ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes scar severity ‐ Neodymium‐doped yttrium aluminium garnet (Nd:YAG)… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.45 [0.88, 2.41]
Studies not reported
Very low
Scar severity: Nd:YAG laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ patient self‐assessment of scar improvement of 50% or higher ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes scar severity: Nd:YAG laser plus Diprospan plus 5‐FU versus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.38 [0.91, 2.1]
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects: Nd:YAG laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
1 finding from 1 review
7
Studies not reported
Very low
Scar severity ‐ Helium‐Neon (He‐Ne) laser plus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream versus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream ‐ Vancouver Scar scale (VSS) (higher scores... · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ regrowth ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.5 [0.27, 8.22]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ pain related to treatment ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 3
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ hyperpigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 5
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ depigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1 [0.07, 15.12]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ purpura ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 15
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ total ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 4.67 [1.53, 14.26]
Studies not reported
Very low